Purpose: To investigate the correlation between SUVmax of FDG-PET/CT and pathological findings including prognostic factors in early-stage T1-T2 breast cancer patients with no LN metastasis. Materials and Methods: Thi...Purpose: To investigate the correlation between SUVmax of FDG-PET/CT and pathological findings including prognostic factors in early-stage T1-T2 breast cancer patients with no LN metastasis. Materials and Methods: This retrospective study investigated 75 patients (mean age 58.9 years;age range 30 - 82 years) with invasive breast cancer who underwent FDG-PET/CT for preoperative staging. All patients underwent subsequent surgery without prior neoadjuvant chemotherapy or endocrine therapy, and those who were confirmed to have T1- or T2-stage by histopathology with no LN metastasis were included. Two patients who had no perceptible FDG accumulation on PET/CT scans were excluded. The correlations between the SUVmax of the tumor and the pathological and immunohistochemical data were evaluated. Results: The mean SUVmax for the total 73 tumors was 5.46 ± 4.05. The mean SUVmax was 3.95 ± 3.28 for the T1 stage group (n = 36) and 7.23 ± 4.10 (p p p p = 0.008), and high Ki-67 status (p < 0.001), respectively. Conclusion: In T1-T2 breast cancer with no LN metastasis, the SUVmax of FDG-PET/CT had significant positive relationships with several prognostic parameters of pathological status. Even in early-stage breast cancer patients, pretreatment FDG-PET/CT is useful for predicting malignant behavior and prognosis).展开更多
目的探究正电子发射计算机体层摄影术(PET)/CT联合胸部能谱CT对肺癌及其分型的诊断价值。方法选择2022年7月至2023年8月在皖北煤电集团总医院收治的疑似肺癌患者70例,其中男性55例,女性15例;年龄37~85岁,平均年龄66.34岁;经病理诊断肺...目的探究正电子发射计算机体层摄影术(PET)/CT联合胸部能谱CT对肺癌及其分型的诊断价值。方法选择2022年7月至2023年8月在皖北煤电集团总医院收治的疑似肺癌患者70例,其中男性55例,女性15例;年龄37~85岁,平均年龄66.34岁;经病理诊断肺癌60例,存在淋巴结转移或远处转移19例,无淋巴结转移或远处转移41例。全部病例均接受PET/CT、能谱CT检查,对比两种检查方式单独及联合对肺癌的诊断效能,对比不同肺癌分型的PET/CT、能谱CT检查特征参数,分析两种检查中各参数单独及联合对腺癌、鳞癌的诊断价值。结果经病理诊断10例非肺癌,60例肺癌,其中非小细胞肺癌54例(腺癌31例、鳞癌21例、鳞腺癌2例)、小细胞肺癌6例。PET/CT检查诊断54例肺癌,16例非肺癌;能谱CT诊断51例肺癌,19例非肺癌。PET/CT+能谱CT诊断出62例肺癌,8例非肺癌。PET/CT+能谱CT诊断肺癌的灵敏度、准确度及阴性预测值高于二者单独诊断,漏诊率低于二者单独诊断(P<0.05)。不同肺癌分型PET/CT检查的最大标准化摄取值(SUVmax)差异明显,非小细胞肺癌PET/CT检查的SUVmax比较,腺癌>鳞癌>鳞腺癌(21.61±1.52>13.60±1.39>6.65±1.27)(P<0.05);小细胞肺癌与非小细胞肺癌SUVmax(14.17±1.82 vs 17.94±1.65)比较,差异有显著统计学意义(P<0.001);不同非小细胞肺癌分型能谱CT检查的有效原子系数、钙含量、碘基值、斜率K比较,差异有统计学意义(P<0.05);小细胞肺癌有效原子系数、钙含量、碘基值、斜率K[7.91±0.08、(6.89±1.68)mg/mL、(11.43±0.79)g/L、2.23±0.24]与非小细胞肺癌比较[7.77±0.12、(3.73±1.36)mg/mL、(7.02±1.18)g/L、1.69±0.30],差异有统计学意义(P<0.05);PET/CT、能谱CT检查各参数联合诊断腺癌、鳞癌的曲线下面积分别为0.923、0.939(P<0.05)。结论PET/CT、胸部能谱CT联合应用可提高对肺癌的诊断效能,且PET/CT、能谱CT检查各参数对不同肺癌分型的有较高诊断价值。展开更多
文摘Purpose: To investigate the correlation between SUVmax of FDG-PET/CT and pathological findings including prognostic factors in early-stage T1-T2 breast cancer patients with no LN metastasis. Materials and Methods: This retrospective study investigated 75 patients (mean age 58.9 years;age range 30 - 82 years) with invasive breast cancer who underwent FDG-PET/CT for preoperative staging. All patients underwent subsequent surgery without prior neoadjuvant chemotherapy or endocrine therapy, and those who were confirmed to have T1- or T2-stage by histopathology with no LN metastasis were included. Two patients who had no perceptible FDG accumulation on PET/CT scans were excluded. The correlations between the SUVmax of the tumor and the pathological and immunohistochemical data were evaluated. Results: The mean SUVmax for the total 73 tumors was 5.46 ± 4.05. The mean SUVmax was 3.95 ± 3.28 for the T1 stage group (n = 36) and 7.23 ± 4.10 (p p p p = 0.008), and high Ki-67 status (p < 0.001), respectively. Conclusion: In T1-T2 breast cancer with no LN metastasis, the SUVmax of FDG-PET/CT had significant positive relationships with several prognostic parameters of pathological status. Even in early-stage breast cancer patients, pretreatment FDG-PET/CT is useful for predicting malignant behavior and prognosis).
文摘目的探究正电子发射计算机体层摄影术(PET)/CT联合胸部能谱CT对肺癌及其分型的诊断价值。方法选择2022年7月至2023年8月在皖北煤电集团总医院收治的疑似肺癌患者70例,其中男性55例,女性15例;年龄37~85岁,平均年龄66.34岁;经病理诊断肺癌60例,存在淋巴结转移或远处转移19例,无淋巴结转移或远处转移41例。全部病例均接受PET/CT、能谱CT检查,对比两种检查方式单独及联合对肺癌的诊断效能,对比不同肺癌分型的PET/CT、能谱CT检查特征参数,分析两种检查中各参数单独及联合对腺癌、鳞癌的诊断价值。结果经病理诊断10例非肺癌,60例肺癌,其中非小细胞肺癌54例(腺癌31例、鳞癌21例、鳞腺癌2例)、小细胞肺癌6例。PET/CT检查诊断54例肺癌,16例非肺癌;能谱CT诊断51例肺癌,19例非肺癌。PET/CT+能谱CT诊断出62例肺癌,8例非肺癌。PET/CT+能谱CT诊断肺癌的灵敏度、准确度及阴性预测值高于二者单独诊断,漏诊率低于二者单独诊断(P<0.05)。不同肺癌分型PET/CT检查的最大标准化摄取值(SUVmax)差异明显,非小细胞肺癌PET/CT检查的SUVmax比较,腺癌>鳞癌>鳞腺癌(21.61±1.52>13.60±1.39>6.65±1.27)(P<0.05);小细胞肺癌与非小细胞肺癌SUVmax(14.17±1.82 vs 17.94±1.65)比较,差异有显著统计学意义(P<0.001);不同非小细胞肺癌分型能谱CT检查的有效原子系数、钙含量、碘基值、斜率K比较,差异有统计学意义(P<0.05);小细胞肺癌有效原子系数、钙含量、碘基值、斜率K[7.91±0.08、(6.89±1.68)mg/mL、(11.43±0.79)g/L、2.23±0.24]与非小细胞肺癌比较[7.77±0.12、(3.73±1.36)mg/mL、(7.02±1.18)g/L、1.69±0.30],差异有统计学意义(P<0.05);PET/CT、能谱CT检查各参数联合诊断腺癌、鳞癌的曲线下面积分别为0.923、0.939(P<0.05)。结论PET/CT、胸部能谱CT联合应用可提高对肺癌的诊断效能,且PET/CT、能谱CT检查各参数对不同肺癌分型的有较高诊断价值。
